CLIC Sargent welcomes the results of a major European trial which shows that children with a high-risk form of neuroblastoma will benefit from a treatment regime that improves survival and reduces side-effects.
Clare Laxton, Assistant Director of Policy and Influencing at CLIC Sargent, said:
“We warmly welcome the result of this trial and that it has found a treatment regime which seems to be more effective for children with this type of neuroblastoma as well as reducing the side-effects felt by young patients. This shows the importance of children with cancer having access to treatment trials.”
The research involved teams across Europe working together, including Professor Andrew Pearson, who devised the trial – and who until his retirement was Professor of Paediatric Oncology at The Institute of Cancer Research, London, and Consultant at The Royal Marsden NHS Foundation Trust.
For more information, please call our Media and PR team on +44 (0)20 8752 2812 or email: email@example.com.